1	Title: Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in
2	Patients with Non-valvular Atrial Fibrillation and Liver Cirrhosis
3	
4	Tien-Shin Chou, MD ^{1, 5} , Yuan Lin, MD ^{2,5} , Ming-Lung Tsai, MD ⁴ , Chin-Ju Tseng,
5	MD ³ , Jhih-Wei Dai, MD ³ , Ning-I Yang, MBChB ³ , Chih-Lang Lin, MD ¹ , Li-Wei
6	Chen, MD ¹ , Ming-Jui Hung, MD, PhD ³ , Tien-Hsing Chen, MD ^{3,5,6}
7	
8	
9	^{1.} Division of Gastroenterology, Department of Internal Medicine, Keelung Chang
10	Gung Memorial Hospital, Keelung Taiwan
11	^{2.} Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital,
12	Keelung, Taiwan
13	^{3.} Division of Cardiology, Department of Internal Medicine, Keelung Chang Gung
14	Memorial Hospital, Keelung Taiwan
15	^{4.} Division of Cardiology, Department of Internal Medicine, New Taipei Municipal
16	TuCheng Hospital, Taiwan
17	^{5.} Chang Gung University College of Medicine, Taoyuan, Taiwan
18	^{6.} Center of data science and Biostatistics, Keelung Chang Gung Memorial Hospital,
19	Taiwan
20	
21	Short title: DOAC in AF and cirrhosis
22	
23	Address for Co-Correspondence:
24	Tien-Hsing Chen, MD
25	Department of Cardiology, Chang Gung Memorial Hospital, Keelung, Taiwan
26	222, Maijin Road, Keelung, Taiwan, R.O.C
27	Tel: +886-2-24313131; Fax: +886-2-24313161
28	E-mail: <u>skyheart0826@gmail.com</u>
29	
30	Words count: 3534 (Text not include the title page, abstract, references, tables, and
31	figure legends.)
32	Words count: 7596 (including title page, abstract, text, references, tables and figures
22	1

33 legends) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 Abstract

35	Background: Evidence of the pharmacodynamics of direct oral anticoagulants
36	(DOACs) is limited in patients with atrial fibrillation (AF) and liver cirrhosis (LC).
37	This study aimed to compare the efficacy and safety of DOACs versus warfarin in
38	patients with non-valvular AF and LC.
39	Methods: We conducted a new-user, retrospective cohort study involving patients
40	with AF and LC from the Chang Gung Hospital System for the years 2012–2021. LC
41	was categorized per the Child-Pugh classification system. We divided the included
42	patients into two cohorts, namely a DOAC cohort and a warfarin cohort. The
43	measured outcomes were thromboembolic events (ischemic stroke [IS], transient
44	ischemic attack [TIA], and systemic embolism [SE]), intracranial hemorrhage [ICH],
45	gastrointestinal (GI) and major bleeding, and all-cause mortality.
46	Results: In total, 478 DOAC users and 247 warfarin users were included in the
47	analysis. DOACs and warfarin exhibited comparable efficacy in preventing
48	thromboembolic events, namely IS (adjusted hazard ratio [aHR], 1.05; 95%
49	confidence interval [CI], 0.42–2.61), TIA (aHR, 1.36; 95% CI, 0.18–10.31]), and SE
50	(aHR, 0.49; 95% CI, 0.14–1.70). DOAC use was associated with a similar risk of
51	ICH (aHR, 0.65; 95% CI, 0.26–1.59) and GI bleeding (aHR, 0.64; 95% CI, 0.39–
52	1.03), a decreased risk of major bleeding (aHR, 0.64; 95% CI, 0.42–0.99), and a
53	reduction in all-cause mortality (aHR, 0.73; 95% CI, 0.54-0.99). Patients with Child-
54	Pugh class A classification exhibited a significant reduction in major bleeding risk in
55	DOAC users (aHR, 0.48; 95% CI, 0.33-0.70); however, this reduction was
56	nonsignificant for patients with class B or C classification (aHR, 0.77; 95% CI,
57	0.54–1.08)
58	Conclusion: Relative to warfarin, DOACs provide comparable efficacy but greater
59	safety for patients with non-valvular AF and LC. Specifically, DOAC use leads to a
60	lower risk of major bleeding and a lower all-cause mortality.
61 62 63 64 65 66 67 68 69 70	

71 Clinical Perspective

72 What is New?

- This study reveals that direct oral anticoagulants (DOACs) and warfarin have
 similar effectiveness in preventing thromboembolic events in patients with non valvular atrial fibrillation (AF) and liver cirrhosis (LC).
- DOACs demonstrate a lower risk of major bleeding and reduced all-cause
 mortality compared to warfarin, especially in patients with Child–Pugh class A
 LC.
- The safety profile of DOACs in reducing gastrointestinal bleeding is comparable
 to that of warfarin, with a trend towards lower risk.

2 What are the Clinical Implications?

- For patients with non-valvular AF and LC, particularly those with Child–Pugh
 class A classification, DOACs may be a safer alternative to warfarin due to their
 lower risk of major bleeding.
- Clinicians can consider DOACs as a comparable alternative to warfarin for
 stroke prevention in this patient group, given their similar efficacy in preventing
 thromboembolic events.
- The reduced all-cause mortality associated with DOACs highlights their
 potential benefit in improving overall patient outcomes in the context of AF and
 LC.

111 Introduction

112

Liver cirrhosis (LC) is a risk factor for atrial fibrillation (AF), and the prevalence rate of AF increases with the severity of liver disease.(1, 2). In AF management, anticoagulation therapy is a crucial component. However, when AF and LC coexist, a key challenge for implementing anticoagulation therapy is balancing the benefits of stroke prevention against the increased risk of bleeding; this challenge is related to the multifaceted hemostatic changes and altered drug metabolism induced by liver disease (3, 4).

120 In the general AF population, direct oral anticoagulants (DOACs) have been 121 demonstrated to be effective for stroke prevention, and they pose a lower risk of 122 bleeding compared with warfarin (5). However, the efficacy and safety of DOACs in 123 patients with both AF and LC are less clear. DOACs provide several advantages, 124 including simplified dosing adjustments based on renal function, limited drug-diet 125 interactions, and minimal coagulation monitoring requirements (6). Because DOACs 126 are less dependent on liver clearance relative to warfarin, they can be advantageous 127 for patients with LC (7). However, evidence of the pharmacodynamics of DOACs in 128 patients with LC is limited because most clinical trials exclude patients with severe 129 liver disease (8-11).

On the basis of the Child-Pugh classification system, current guidelines 130 131 advocate the administration of oral anticoagulants for patients with LC (12-14). For 132 patients with class A LC, all four currently available DOACs are regarded as 133 appropriate. For those with class B LC, dabigatran, apixaban, and edoxaban should be 134 administered with caution, whereas the use of rivaroxaban is discouraged. For 135 patients with class C LC, DOACs are not recommended (12-14). Nonetheless, most of the data supporting these guidelines were derived from small-scale clinical studies 136 137 (15, 16) or extrapolated from noncirrhotic populations(17-20). That is, these data were not based on comprehensive clinical and laboratory information with accurate 138 139 definitions of liver disease severity (17-20). Furthermore, real-world studies have 140 yielded inconclusive and inconsistent data regarding the effectiveness and safety of 141 DOACs in patients with liver disease (17-19). Lee SR et al. reported that the clinical 142 outcomes of DOAC and warfarin use in patients with LC were not significantly 143 different (17). By contrast, Lee HF et al. reported a lower risk of gastrointestinal (GI) 144 bleeding in DOAC users than in warfarin users (18), and Lawal et al. observed that

145 relative to warfarin users, DOAC users were exposed to a comparable risk of major GI bleeding but to lower risks of all-cause mortality and major bleeding (19). These 146 147 inconsistent findings and the limited event data pertaining to this topic highlight the 148 necessity of conducting more focused and rigorous research in this area.

149 Thus, we enrolled cohorts of patients with both AF and LC who were treated 150 with either DOACs or warfarin. Our objective was to investigate the comparative 151 efficacy and safety of DOACs versus warfarin in patients with AF across the 152 spectrum of LC severity.

153

154 **Methods**

155 Data source

156 The data were retrieved from the Chang Gung Research Database (21). Due to retrospective nature of the database study, the hospital identification number of each 157 158 patient was encrypted and de-identified to protect their privacy. Therefore, informed consent was waived for this study. The institutional review board of Chang Gung 159 160 Memorial Hospital approved the study protocol (IRB No. :202200625B0).

161

162 Study Population and Exposure

163 The study cohort comprised patients with both nonvalvular AF and LC who 164 were exposed to DOACs (apixaban, dabigatran, rivaroxaban, or edoxaban) or 165 warfarin between January 1, 2012, and December 31, 2021. The index day was defined as the first day on which a DOAC or warfarin was prescribed. Patients with 166 LC were included if they met two criteria. First, they were required to be clinically 167 diagnosed with LC. Second, this diagnosis was required to be validated through a 168 169 manual review of reports of abdominal ultrasound or transient elastography 170 (FibroScan, liver stiffness > 12 kPa) conducted 3 years before or 6 months after the 171 index day (22, 23). Patients were excluded if they lacked abdominal ultrasound or 172 transient elastography data, their abdominal ultrasound or transient elastography 173 results did not provide any evidence of LC, they had a history of liver transplantation, their demographic (age and sex) or Child-Pugh score data were incomplete, they 174 175 were aged <20 years, they had valvular AF, they had prior venous thromboembolism, 176 they were undergoing dialysis for end-stage renal disease, or they were lost to follow-177 up. Furthermore, we divided the included patients into a DOAC group and a warfarin 178 group (Figure 1).

179

180 Clinical outcomes

The primary outcomes were efficacy and safety outcomes. The efficacy 181 outcomes were ischemic stroke (IS), transient ischemic attack (TIA), systemic 182 183 embolism (SE), and a composite measure of IS, TIA, and SE (IS/TIA/SE). The safety 184 outcomes were intracranial hemorrhage (ICH), GI bleeding, and major bleeding. The 185 secondary outcomes were all-cause mortality, myocardial infarction (MI), and liver decompensation outcomes. The liver decompensation outcomes were hepatic 186 187 encephalopathy, ascites, spontaneous bacterial infection, hepatorenal syndrome, esophageal variceal bleeding, hepatocellular carcinoma (HCC), and liver related 188 189 death. Comorbidities and diseases were detected by referencing International Classification of Diseases, 9th and 10th Revision, Clinical Modification (ICD-9-CM 190 191 and ICD-10-CM) codes (Supplemental Table S1). Most of the clinical events were identified through inpatient diagnoses, with the exceptions being ascites, and all-192 193 cause mortality. Information on the date and cause of death was retrieved from the 194 Taiwan Death Registry database. Ascites was defined as newly detectable ascites that 195 were clinically confirmed by ultrasound findings. The end of the study period was the 196 date of death, December 31, 2021, the final clinical visit, or the fifth year of follow-197 up, whichever occurred first.

198

199 Covariate measurement

200 The covariates examined in the present study were demographics (i.e., age, sex, 201 smoking habit, alcohol drinking habit, and body mass index), duration of LC, LC-202 related diseases (e.g., primary biliary cholangitis), LC complications (e.g., ascites), 203 comorbidities (i.e., diabetes mellitus, hypertension, and four others), historical events 204 requiring hospitalization (i.e., ischemic stroke, major bleeding, and six others), 205 medications concurrently prescribed at outpatient clinics (i.e., aspirin, beta-blockers, 206 and 16 other medications), risk scores (i.e., Child-Pugh score, CHA2DS2-VASc 207 score, HAS-BLED score, and Charlson comorbidity index score), liver function test (i.e., serum aspartate aminotransferase and alanine aminotransferase, platelet count, 208 209 prothrombin time, bilirubin level, and albumin level), and various laboratory data 210 (e.g., international normalized ratio [INR]). A comorbidity was included in this study 211 if two outpatient diagnoses or one discharge diagnosis was made for the comorbidity 212 prior to the index date. Laboratory data within 3 months prior to the index date were

retrieved. Liver function test results and esophagogastroduodenoscopy results were
retrieved from records dating to 3 years prior to and 6 months after the index date.
Concurrent medication use was determined using records dating to 3 months before
or after the index date. Portal hypertension was defined as the presence of ascites,
varices, or splenomegaly (24). The classification of liver disease severity based on
Child–Pugh scores is described in Supplemental Table S2.

219

220 Statistical analysis

221 Because substantial differences in baseline demographics and clinical 222 characteristics were identified between the DOAC and warfarin groups, inverse 223 probability of treatment weighting (IPTW), which is based with on the average 224 treatment effect and propensity scores, was performed to ensure comparability 225 between the two groups. We estimated the propensity score using a generalized 226 boosted model (GBM), which was constructed using 50,000 regression trees. All the 227 covariates (Table 1) were included in the estimation of propensity scores; the follow-228 up year was replaced by the index date. The balance of baseline data between the two 229 groups before and after GBM-IPTW was evaluated by calculating standardized 230 difference (STD), where an absolute STD value of <0.2 indicated a non-substantial 231 group difference. Because of the substantial amount of missing values in the 232 continuous laboratory data, the missing data were imputed using an expectation-233 maximization algorithm. We compared outcomes in both the imputed and IPTW-234 adjusted cohorts.

235 We employed the Cox proportional hazard model to compare the risk of fatal 236 time-to-event outcomes (e.g., liver-related death) between the DOAC and warfarin 237 groups. The Fine-Gray sub-distribution hazard model was used to compare the 238 incidence of nonfatal time-to-event outcomes (e.g., ischemic stroke and major 239 bleeding) between the two groups; all-cause mortality during follow-up was 240 considered as a competing risk in this model. Given the potential covariate 241 imbalances between the two groups, even after thorough GBM-IPTW, including imbalances pertaining to age, age groups, esophageal/gastric varice-related 242 243 complications, portal hypertension, radiofrequency ablation, P2Y12, other betablockers, CHA_2DS_2 -VASc score, INR value, and INR status (absolute STD > 0.2), 244 245 the aforementioned survival regression models were further adjusted for these 246 covariates. Finally, a subgroup analysis of the primary safety outcome (i.e., major

247 bleeding) was performed, and the results were stratified by clinical variables in the

IPTW-adjusted cohort. SAS (version 9.4, SAS Institute) was used for statistical 248

249 analyses. A two-sided *P* value of <0.05 was regarded as statistically significant.

- 250
- 251

252 **Results**

253 **Baseline** characteristics

254 From the Chang Gung Research Database, we identified 1,932 patients with AF

255 and LC who were treated with oral anticoagulants between January 1, 2012, and

256 December 31, 2021. Among them, 725 patients met the eligibility criteria for

257 inclusion in the present study (Figure 1). Table 1 presents the baseline characteristics

258 of the study population, and the patients treated with DOACs (n = 478) were

259 compared with those treated with warfarin (n = 247). After IPTW adjustment, the

260 distribution of Child–Pugh classes was comparable between the DOAC group and the

261 warfarin group (Child–Pugh A, 53.9% vs. 45.3%; STD = -0.17; Child–Pugh B,

40.5% vs. 47.4%; STD = -0.14; Child–Pugh C, 5.6% vs. 7.3%; STD = -0.07). 262

263 However, the DOAC group had higher CHA2DS2-VASc scores (DOAC vs. warfarin,

264 3.5 vs. 3.1) and HAS-BLED scores (DOAC vs. warfarin, 3.9 vs. 3.6) relative to the

265 warfarin group. Additionally, the DOAC group had a lower prevalence of portal

266 hypertension (DOAC vs. warfarin, 74.3% vs. 85.2%), higher mean age (DOAC vs.

warfarin, 72.2 years vs. 67.8 years), and lower INR level (DOAC vs. warfarin, 1.2 vs. 267

268 1.4) relative to the warfarin group. The average follow-up durations for the DOAC

and warfarin groups were 2.6 and 3.2 years, respectively. 269

270

271 Clinical outcomes

272 For the maximum 5-year follow-up period, the results revealed that DOACs were as effective as warfarin in reducing the incidence of the composite outcome 273 274 (IS/TIA/SE; adjusted hazard ratio [aHR], 0.76; 95% confidence interval [CI], 0.38-275 1.53) (Table 2 and Figure 2A). The primary efficacy outcomes did not differ significantly between the two groups. Regarding safety outcomes, while there was no 276 277 significant difference in intracranial hemorrhage (ICH) between the two groups, DOACs demonstrated a non-significant trend toward a lower risk of GI bleeding 278 279 (aHR, 0.64; 95% CI, 0.39–1.03) and a significantly lower risk of major bleeding 280 (aHR, 0.64; 95% CI, 0.42–0.99) relative to the warfarin group (Figure 2B).

281 Furthermore, the DOAC group exhibited a significantly lower risk of all-cause mortality (aHR, 0.73; 95% CI, 0.54-0.99) (Figure 2C). The DOAC and warfarin 282 283 groups exhibited similar levels of MI risk (aHR, 1.20; 95% CI, 0.26–5.61; P = 0.815). 284 Regarding liver decompensation outcomes, no significant differences were observed 285 between the two groups (Table 2). Supplemental Figure S1 provides details on the 286 causes of death.

287

288 Subgroup analysis

289 In the subgroup analysis of major bleeding, the beneficial effect of DOACs in 290 reducing major bleeding risk did not significantly differ across various factors, 291 namely age, gender, portal hypertension, diabetes mellitus, malignancy, HAS-BLED 292 score, albumin level, total bilirubin level, and INR status (Supplemental Table S3). 293 However, the beneficial effect of DOACs was more in patients with HCC than in those without HCC (aHR, 0.38 vs. 0.72; P for interaction = 0.02). We further 294 295 stratified our results by Child-Pugh class and discovered that patients with Child-296 Pugh class A classification exhibited a significant reduction in major bleeding risk in DOAC users (aHR, 0.48; 95% CI, 0.33-0.70); however, this reduction was 297 298 nonsignificant for patients with class B or C classification (aHR, 0.77; 95% CI, 299 0.54-1.08) (Figure 3A and 3B).

300

Discussion 301

In the present cohort study, we evaluated the efficacy and safety of DOACs 302 versus warfarin among 725 patients with non-valvular AF and LC of varying severity. 303 Our findings indicated that DOACs and warfarin were similarly effective in 304 305 preventing thromboembolic events, namely IS, TIA, and SE. Compared with warfarin 306 users, DOAC users exhibited similar ICH risk and a non-significantly lower risk of 307 GI bleeding. DOAC use was associated with a lower risk of major bleeding, 308 especially in patients with Child–Pugh class A LC. DOAC use was associated with 309 lower all-cause mortality. Regarding liver decompensation outcomes, no significant differences were observed between the DOAC and warfarin groups. Overall, DOAC 310 311 and warfarin users exhibited similar efficacy and safety with respect to ICH and GI bleeding. However, relative to warfarin, DOACs exhibited superior safety in reducing 312 313 major bleeding events; this finding provides essential guidance when deciding whether to administer anticoagulation therapy for patients with AF and LC. 314

315

For patients with LC, DOACs and warfarin have been reported to lead to similar 316 317 outcomes with respect to stroke and SE (17-19). In our study, patients with LC who 318 used DOACs exhibited similar levels of IS and SE risk relative to those who used 319 warfarin. The pathophysiological mechanism underlying the association between LC and stroke is complex and multifactorial. Clinical evidence has debunked the 320 321 misconception that natural anticoagulation occurs in patients with LC (25). Notably, 322 the risk of ischemic stroke has been reported to be higher in patients with AF and LC 323 than in patients with AF alone (26). Chronic liver disease, particularly LC, increases thrombosis risk because of the impaired synthesis of endogenous anticoagulants such 324 325 as protein C, protein S, and antithrombin (25). This risk is intensified because of the 326 combined effects of several factors in patients with LC, namely the release of factor 327 VIII and von Willebrand factor stimulated by lipopolysaccharides from bacterial translocation; the reduction in ADAMTS13 levels, which modulates von Willebrand 328 329 factor activity; and hypofibrinolysis due to low plasminogen levels (27, 28). 330 Furthermore, in patients with LC, interleukin-6, which is frequently elevated in 331 response to endotoxemia (29, 30), increases tissue factor expression on activated 332 monocytes and endothelial cells (31). This cascade amplifies systemic inflammation, 333 impairs the coagulation pathway, and potentially increases the risk of stroke in 334 patients with LC (32, 33). In our study cohort, these LC-related factors could have 335 precipitated stroke and reduced the protective effect of DOACs, possibly explaining 336 the absence of a significant effect on stroke outcomes.

337

338 Compared with warfarin use, DOAC use was reported to be associated with a 339 lower risk of ICH in several key randomized controlled trials (8-11). In the present 340 study, a similar level ICH risk was also observed among DOAC users. A proposed hypothesis is that DOACs, by not interfering with the formation of tissue factor and 341 342 factor VIIa complexes, may support cerebral hemostatic mechanisms (34). 343 Additionally, the interactions of DOACs with the P-glycoprotein transport system and their potential ability to limit endothelial cell damage within the blood-brain barrier 344 345 (mediated by the thrombin/Protease-Activated Receptor-1 pathway) may contribute to 346 their superior safety profile in preventing ICH (34-36). Another plausible hypothesis 347 is that anticoagulants disrupt the coagulation pathway, which promotes the accelerated extravasation of red blood cells, the accumulation of cerebral 348

349 microhemorrhages (CMBs), and, eventually, leads to the development of 350 symptomatic ICH (37). This hypothesis is supported by a study that reported a lower 351 incidence of new CMB among DOAC users than among warfarin users in a 352 population treated for AF (38). However, findings have been inconsistent regarding 353 the association of ICH risk with DOAC use in the context of liver disease (17, 18). 354 Increased liver fibrosis may be independently associated with an increased burden of 355 CMB, but the mechanism underlying this association remains unclear (39). 356 Furthermore, patients with LC exhibit an increased risk of hemorrhagic stroke (40). 357 Although DOACs can marginally reduce the risk of ICH in patients without LC, the complex nature of ICH development may diminish this protective effect in patients 358 359 with LC. This supports our finding that DOAC and warfarin users exhibit similar 360 levels of ICH risk.

361

The present study revealed that relative to warfarin users, DOAC users tended to 362 363 exhibit a reduced risk of GI bleeding and had a decreased risk of major bleeding. The 364 superior safety profiles of DOACs relative to warfarin may be attributed to their more 365 predictable pharmacokinetics, lower dependence on liver clearance, and fewer 366 interactions with various drugs and foods. Furthermore, bacterial overgrowth in the 367 small intestine, which is commonly observed in patients with LC, particularly those 368 with advanced liver disease and portal hypertension, may alter gut microbiota (41, 42). This change can lead to a net decrease in vitamin K availability, which may amplify 369 370 the anticoagulant effect of warfarin, thereby increasing the risks of overanticoagulation and bleeding (43). The aforementioned factors may have collectively 371 372 contributed to the observed reduction in the risks of major and GI bleeding. 373 Compared with the cohorts of other studies, our cohort exhibited several distinct 374 differences. First, our cohort had a lower HAS-BLED score relative to that of a 375 nationwide U.S. study that included not only patients with LC but also those with less 376 severe liver diseases (19). Despite the lower HAS-BLED score, our study revealed higher risks of both major and GI bleeding. This finding indicates that the HAS-377 BLED score should be further validated to more accurately predict the bleeding risk 378 379 associated with anticoagulant use in patients with LC. Second, Lawal et al. categorized patients with LC into those with compensated or decompensated LC, and 380 381 they did not identify any differences in clinical outcomes (including major and GI bleeding) between DOAC and warfarin users (19). Conversely, our analysis 382

383 highlighted the safety benefits of DOAC, particularly with respect to major bleeding, for patients with Child-Pugh class A LC. Additionally, DOACs demonstrated a trend 384 385 towards a reduction in GI bleeding risk in our cohort, although this trend did not 386 reach statistical significance.

387 In our study, the risk of all-cause mortality was lower among DOAC users than 388 among warfarin users, and this trend was most pronounced for liver-related deaths 389 (Supplemental Figure S1). While a study found that the mortality benefit of DOAC 390 may be related to the reduced risk in ICH (44), our study observed a comparable risk 391 of ICH with DOAC use. This suggests that the advantage of DOAC in reducing allcause mortality may be partly due to a decrease in liver-associated complications, 392 393 though the underlying biological mechanisms for this effect remain to be elucidated. 394 A study highlighted the mortality-reducing effects of vitamin K1 in patients with LC 395 (45), providing a backdrop for exploring the interplay between anticoagulants and 396 vitamin K. Additionally, a meta-analysis revealed that patients experiencing ICH 397 while on DOACs had smaller hematoma sizes and lower mortality rates at discharge 398 compared to those on vitamin K antagonists (46). This indicates that DOACs are 399 associated with less severe outcomes in the event of ICH, potentially contributing to 400 their overall mortality benefit. Furthermore, nearly half of our study participants were 401 diagnosed with diabetes mellitus. The benefits of vitamin K in enhancing insulin 402 sensitivity and mitigating inflammation raises questions about whether warfarin's 403 inhibition of vitamin K may exacerbate glucose control and inflammatory responses 404 (47). A supporting study reported lower mortality rates among DOAC users than 405 among warfarin users in patients with AF and diabetes mellitus (48). Nevertheless, 406 the aforementioned hypotheses represent preliminary interpretations, and more 407 rigorous research is required to confirm them.

408

409 Limitations

Our study has several limitations: 1. Patient Cohort: Our cohort consists mostly 410 of patients with milder forms of LC, which limits our findings' applicability to 411 advanced LC (Child-Pugh classes B and C). However, the relevance of stroke 412 413 prevention for patients with Child–Pugh class B and C LC, who often have a limited 414 life expectancy, may be reduced. Thus, the long-term effects of DOACs in these 415 classes may be less crucial. 2. Differential Effects of DOACs: Although each DOAC 416 has a distinct pharmacological profile, our study did not separately examine the safety

417 and efficacy of each DOAC in this cohort. Notably, a study reported a higher bleeding risk in rivaroxaban users than in apixaban users (49). Because of the limited 418 419 number of participants in each DOAC class, our study did not have adequate 420 statistical power for the further analysis of each DOAC. 3. Methodological 421 Limitation: We employed IPTW to mitigate biases when comparing DOACs and 422 warfarin. However, retrospective studies inherently harbor confounders, which hinder 423 the confirmation of causality between DOAC use and outcomes, and only randomized controlled trials or prospective studies can yield conclusive evidence. 4. 424 425 Generalizability: The present study's geographical context and predominant LC etiology restrict its general applicability. Specifically, it was conducted within the 426 427 context of an East Asian health-care system where viral hepatitis and alcohol are the primary causes of LC. Therefore, our results may not be generalized to patients with 428 429 liver diseases resulting from nonalcoholic steatohepatitis, although literature findings suggest that the pharmacokinetics of apixaban are unaffected by nonalcoholic 430 431 steatohepatitis (50).

432

433 Conclusion

In the present study, DOACs and warfarin demonstrated comparable effectiveness in preventing thromboembolic events, namely IS, TIA, and SE. However, compared to warfarin, DOAC use resulted in lower rates of major bleeding, particularly in patients with Child–Pugh class A LC, while demonstrating comparable effects on the risks of ICH and GI bleeding. DOACs were associated with reduced all-cause mortality. Our research provides a real-world perspective that can help to guide clinicians in anticoagulation decision-making for patients with AF and LC.

	-	

458 Acknowledgments

- 459 The authors thank the statistical assistance and wish to acknowledge the support of
- 460 the Maintenance Project of the Center of data science and Biostatistics (Grant
- 461 CGRPG2F0011, CLRPG2C0021, CLRPG2C0022, CLRPG2C0023, CLRPG2C0024,
- 462 CLRPG2G0081, CLRPG2G0082, CLRPG2G0083, CLRPG2L0021, CLRPG2L0022,
- and CMRPG2N0041) at Keelung Chang Gung Memorial Hospital for study design
- 464 and monitor, data analysis and interpretation.

Sources of Funding:

- 467 This work was supported by grants from the Chang Gung Memorial Hospital, Taiwan
- 468 (CMRPG2N0041).
- **Disclosures:**
- 471 None.

perpetuity. All rights reserved. No reuse allowed without permission.

479 480 481 482 483 484 485 **Reference:** 486 Lee H, Choi EK, Rhee TM, Lee SR, Lim WH, Kang SH, et al. Cirrhosis is a risk 1. 487 factor for atrial fibrillation: A nationwide, population-based study. Liver Int. 2017;37(11):1660-7. 488 489 Huang WA, Dunipace EA, Sorg JM, Vaseghi M. Liver Disease as a Predictor of 2. 490 New-Onset Atrial Fibrillation. J Am Heart Assoc. 2018;7(15):e008703. 491 3. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Torres-Ortiz A, 492 O'Corragain OA, Watthanasuntorn K, et al. Efficacy and safety of anticoagulation for 493 atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis. 494 Dig Liver Dis. 2019;51(4):489-95. 495 Lewis JH, Stine JG. Review article: prescribing medications in patients with 4. 496 cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132-56. 497 5. Chiang CE, Chao TF, Choi EK, Lim TW, Krittayaphong R, Li M, et al. Stroke 498 Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 1). JACC 499 Asia. 2022;2(4):395-411. 500 Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic 6. 501 patient. JHEP Rep. 2019;1(3):227-39. 502 Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral 7. 503 Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol. 2018;71(19):2162-504 75. 505 8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. 506 Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 507 2009;361(12):1139-51. 508 Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. 9. 509 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 510 2011;365(10):883-91. 511 10. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. 512 Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. 513 514 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. 11. 515 Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 516 2011;365(11):981-92. 517 Chiang CE, Chao TF, Choi EK, Lim TW, Krittayaphong R, Li M, et al. Stroke 12. 518 Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2). JACC 519 Asia. 2022;2(5):519-37. 520 13. O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, et al. AGA

521 522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

perpetuity. All rights reserved. No reuse allowed without permission. Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology. 2021;161(5):1615-27 e1. 14. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, et al. 15. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61(6):1721-7. 16. Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017;98(4):393-7. 17. Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, et al. Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. J Am Coll Cardiol. 2019;73(25):3295-308. 18. Lee HF, Chan YH, Chang SH, Tu HT, Chen SW, Yeh YH, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2019;8(5):e011112. 19. Lawal OD, Aronow HD, Shobayo F, Hume AL, Taveira TH, Matson KL, et al. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. Circulation. 2023;147(10):782-94. Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, et al. 20. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol. 2018;264:58-63. 21. Shao SC, Chan YY, Kao Yang YH, Lin SJ, Hung MJ, Chien RN, et al. The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28(5):593-600. Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, et al. Correlation 22. between ultrasonographic and pathologic diagnoses of hepatitis B and C virusrelated cirrhosis. J Gastroenterol. 2003;38(2):153-7. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. 23. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403-8. Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of 24. administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol. 2013;47(5):e50-4.

560 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J 25. 561 Med. 2011;365(2):147-56.

562 Kuo L, Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Liver Cirrhosis in Patients 26. 563 With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for 564 Stroke Prevention? J Am Heart Assoc. 2017;6(6).

565 27. Carnevale R, Raparelli V, Nocella C, Bartimoccia S, Novo M, Severino A, et al.

566 Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells.

567 Implications for hypercoagulability in cirrhosis. J Hepatol. 2017;67(5):950-6. 568 28. Ding WY, Gupta D, Lip GYH. Atrial fibrillation and the prothrombotic state: 569 revisiting Virchow's triad in 2020. Heart. 2020;106(19):1463-8. 570 29. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma interleukin-6 levels 571 in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, 572 and hyperdynamic circulation. Scand J Gastroenterol. 1996;31(5):500-5. 573 Arroyo V, Angeli P, Moreau R, Jalan R, Claria J, Trebicka J, et al. The systemic 30. 574 inflammation hypothesis: Towards a new paradigm of acute decompensation and 575 multiorgan failure in cirrhosis. J Hepatol. 2021;74(3):670-85. 576 Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation 31. activation contributing to organ failure in critically ill patients. Semin Immunopathol. 577 578 2012;34(1):167-79. 579 Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated 32. 580 therapy in ischaemic stroke. Nat Rev Neurol. 2016;12(10):594-604. 581 33. Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic 582 inflammation, and cirrhosis. J Hepatol. 2014;61(2):396-407. 583 34. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et 584 al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and 585 younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. 586 587 Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact 35. 588 or fantasy? Pharmacol Ther. 2009;123(1):80-104. 589 36. Puech C, Delavenne X, He Z, Forest V, Mismetti P, Perek N. Direct oral 590 anticoagulants are associated with limited damage of endothelial cells of the blood-591 brain barrier mediated by the thrombin/PAR-1 pathway. Brain Res. 2019;1719:57-63. 592 37. Wilson D, Werring DJ. Antithrombotic therapy in patients with cerebral 593 microbleeds. Curr Opin Neurol. 2017;30(1):38-47. 594 38. Zhuang L, Zhai L, Qiao S, Hu X, Lai Q, Fu F, et al. New cerebral microbleeds in 595 AF patients on non-vitamin K oral anticoagulants or warfarin: One-year follow-up. 596 Medicine (Baltimore). 2022;101(7):e25836. 597 Kim YD, Song D, Heo JH, Kim SU, Kim BK, Park JY, et al. Relationship between 39. Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. 598 599 PLoS One. 2015;10(9):e0139227. 600 40. Parikh NS, Navi BB, Schneider Y, Jesudian A, Kamel H. Association Between 601 Cirrhosis and Stroke in a Nationally Representative Cohort. JAMA Neurol. 602 2017;74(8):927-32. 603 41. Ghosh G, Jesudian AB. Small Intestinal Bacterial Overgrowth in Patients With 604 Cirrhosis. J Clin Exp Hepatol. 2019;9(2):257-67. 605 Maslennikov R, Pavlov C, Ivashkin V. Small intestinal bacterial overgrowth in 42. 606 cirrhosis: systematic review and meta-analysis. Hepatol Int. 2018;12(6):567-76. 607 Scarpellini E, Gabrielli M, Za T, Lauritano EC, Santoliquido A, Rossi E, et al. The 43. 608 interaction between small intestinal bacterial overgrowth and warfarin treatment. 609 Am J Gastroenterol. 2009;104(9):2364-5. 610 44. Liew A, O'Donnell M, Douketis J. Comparing mortality in patients with atrial 611 fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a metaanalysis of randomized trials. J Thromb Haemost. 2014;12(9):1419-24. 612 613 45. Xiong Z, Liu Y, Chang T, Xu X, Huo S, Deng H, et al. Effect of vitamin K1 on

614 survival of patients with chronic liver failure: A retrospective cohort study. Medicine

615 (Baltimore). 2020;99(13):e19619.

616 46. Ahmed A, Ahmed R, Ali SS, Patel U, Shahid I, Zafar M, et al. Intracerebral 617 hemorrhage outcomes in patients using direct oral anticoagulants versus vitamin K 618 antagonists: a meta-analysis. Clin Neurol Neurosurg. 2020;198:106146.

619 Karamzad N, Maleki V, Carson-Chahhoud K, Azizi S, Sahebkar A, Gargari BP. A 47. 620 systematic review on the mechanisms of vitamin K effects on the complications of 621 diabetes and pre-diabetes. Biofactors. 2020;46(1):21-37.

Huang HK, Liu PP, Lin SM, Hsu JY, Yeh JI, Lai EC, et al. Diabetes-Related 622 48. Complications and Mortality in Patients With Atrial Fibrillation Receiving Different 623 Oral Anticoagulants : A Nationwide Analysis. Ann Intern Med. 2022;175(4):490-8. 624

625 Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, et al. 49.

626 Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA. 2021;326(23):2395-404. 627

628 50. Tirona RG, Kassam Z, Strapp R, Ramu M, Zhu C, Liu M, et al. Apixaban and

629 Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metab 630 Dispos. 2018;46(5):485-92.

631

632 Figure legends

- 633 Figure 1. Flow chart for selecting and excluding patients.
- 634
- 635 Figure 2. Cumulative event rates for primary efficacy outcome (A), major bleeding
- 636 (B), and all-cause mortality (C) during 5-year follow-up period for patients with atrial
- 637 fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-
- 638 adjusted cohort.
- 639 Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of
- 640 treatment weighting.
- 641
- 642 Figure 3. Cumulative event rates for primary safety outcome (major bleeding) during
- 643 5-year follow-up period for patients with atrial fibrillation and liver cirrhosis who
- 644 were administered DOACs or warfarin in IPTW-adjusted cohort; results are classified
- 645 under Child–Pugh class A (A) and Child–Pugh class B or C (B).
- 646 Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of
- 647 treatment weighting.
- 648
- 649
- 650
- 651
- 652
- 653 654
- 655
- -
- 656
- 657
- 658
- 659
- 660
- 661

· · · · ·		Before IPTW an	d imputation#	After IPTW and imputation\$			
	Available	DOAC	Warfarin				
Variable	number	(<i>n</i> = 478)	(<i>n</i> = 247)	STD	DOAC	Warfarin	STD
Age, years	725	73.2 ± 10.9	65.2 ± 12.6	0.68	72.2 ± 11.3	67.8 ± 12.4	0.37
Age group	725						
<65 years		103 (21.5)	122 (49.4)	-0.61	24.8%	39.3%	-0.31
65–74 years		147 (30.8)	64 (25.9)	0.11	30.6%	30.2%	0.01
≥75 years		228 (47.7)	61 (24.7)	0.49	44.6%	30.5%	0.29
Female	725	181 (37.9)	82 (33.2)	0.10	37.6%	33.0%	0.10
Smoking	725	133 (27.8)	80 (32.4)	-0.10	29.0%	29.1%	< 0.01
Alcohol drinking	725	112 (23.4)	63 (25.5)	-0.05	25.1%	23.8%	0.03
Body mass index, kg/m ²	615	26.1 ± 4.9	25.5 ± 4.9	0.12	26.2 ± 4.6	25.6 ± 4.5	0.12
Vital signs							
Systolic blood pressure, mmHg	669	131.2 ± 21.9	130.7 ± 22.3	0.03	131.0 ± 21.2	132.2 ± 22.9	-0.05
Diastolic blood pressure, mmHg	669	75.2 ± 13.2	73.3 ± 13.4	0.14	75.2 ± 12.7	73.7 ± 13.4	0.11
Heart rate, beats/min	667	83.5 ± 18.0	81.2 ± 18.2	0.13	83.5 ± 17.2	80.3 ± 17.2	0.19
Duration of liver cirrhosis, years	725	4.3 ± 5.2	3.5 ± 4.1	0.19	4.1 ± 5.0	3.8 ± 4.6	0.07
Liver cirrhosis related disease							
Alcoholism	725	79 (16.5)	39 (15.8)	0.02	17.6%	13.2%	0.12
HBV infection	725	153 (32.0)	75 (30.4)	0.04	32.0%	33.6%	-0.04
HCV infection	725	152 (31.8)	78 (31.6)	<0.01	30.4%	31.1%	-0.02
Nonalcoholic fatty liver disease	725	46 (9.6)	16 (6.5)	0.12	9.3%	6.5%	0.10
Autoimmune hepatitis	725	5 (1.0)	0 (0.0)	0.15	1.0%	0.0%	0.14
Primary biliary cholangitis	725	6 (1.3)	1 (0.4)	0.09	1.3%	0.5%	0.08
Liver cirrhosis complications							
Ascites	725	147 (30.8)	99 (40.1)	-0.20	32.5%	36.8%	-0.09
EV or GV	725	62 (13.0)	56 (22.7)	-0.26	13.7%	21.9%	-0.22
Hepatic encephalopathy	725	10 (2.1)	15 (6.1)	-0.20	2.3%	5.0%	-0.14
Spontaneous bacterial peritonitis	725	2 (0.4)	1 (0.4)	<0.01	0.4%	1.1%	-0.08

Table 1. Baseline characteristics of patients with atrial fibrillation and liver cirrhosis who were administered DOAC or warfarin.

	Before IPTW and imputation#				After IPTW and imputation\$		
	Available	DOAC	Warfarin				
Variable	number	(<i>n</i> = 478)	(<i>n</i> = 247)	STD	DOAC	Warfarin	STD
HCC	725	123 (25.7)	56 (22.7)	0.07	24.3%	23.6%	0.02
Hepatorenal syndrome	725	4 (0.8)	1 (0.4)	0.06	0.8%	0.4%	0.06
Portal hypertension	725	350 (73.2)	216 (87.4)	-0.36	74.3%	85.2%	-0.27
Treatment for HCC							
Systemic therapy	725	66 (13.8)	37 (15.0)	-0.03	13.0%	16.3%	-0.09
Liver resection	725	5 (1.0)	6 (2.4)	-0.11	0.9%	2.8%	-0.14
Radiofrequency ablation	725	75 (15.7)	21 (8.5)	0.22	15.1%	8.2%	0.21
Transarterial chemoembolisation	725	8 (1.7)	0 (0.0)	0.18	1.5%	0.0%	0.17
Percutaneous injection therapy	725	11 (2.3)	8 (3.2)	-0.06	2.1%	3.1%	-0.06
Comorbidities							
Diabetes mellitus	725	219 (45.8)	110 (44.5)	0.03	46.3%	48.0%	-0.03
Hypertension	725	368 (77.0)	152 (61.5)	0.34	75.9%	68.1%	0.18
Hyperlipidemia	725	147 (30.8)	61 (24.7)	0.14	30.2%	26.1%	0.09
Peripheral artery disease	725	45 (9.4)	34 (13.8)	-0.14	9.1%	13.0%	-0.12
Peptic ulcer disease	725	242 (50.6)	123 (49.8)	0.02	50.7%	51.4%	-0.01
Malignancy	725	222 (46.4)	101 (40.9)	0.11	45.0%	43.4%	0.03
History of events requiring hospitalization							
Systemic thromboembolism	725	11 (2.3)	13 (5.3)	-0.16	2.3%	4.5%	-0.12
Ischemic stroke	725	71 (14.9)	31 (12.6)	0.07	15.6%	10.1%	0.17
Transient ischemic attack	725	8 (1.7)	10 (4.0)	-0.14	1.5%	2.7%	-0.09
Intracranial hemorrhage	725	31 (6.5)	7 (2.8)	0.17	5.8%	2.4%	0.18
Myocardial infarction	725	26 (5.4)	9 (3.6)	0.09	5.3%	3.5%	0.09
Coronary revascularization	725	32 (6.7)	11 (4.5)	0.10	6.4%	3.2%	0.15
Heart failure	725	122 (25.5)	71 (28.7)	-0.07	26.1%	27.9%	-0.04
Major bleeding	725	122 (25.5)	48 (19.4)	0.15	24.6%	20.9%	0.09
Medications							
Aspirin	725	126 (26.4)	54 (21.9)	0.11	27.4%	21.0%	0.15

	E	Before IPTW and	d imputation#	After IPTW and imputation\$			
	Available	DOAC	Warfarin				
Variable	number	(<i>n</i> = 478)	(<i>n</i> = 247)	STD	DOAC	Warfarin	STD
P2Y12	725	75 (15.7)	17 (6.9)	0.28	15.6%	7.6%	0.25
Amiodarone/dronedarone	725	72 (15.1)	30 (12.1)	0.09	14.9%	12.7%	0.06
Digoxin	725	47 (9.8)	51 (20.6)	-0.30	10.3%	17.1%	-0.20
ACEi/ARBs	725	244 (51.0)	104 (42.1)	0.18	50.9%	44.1%	0.14
Beta-blockers							
Propranolol	725	33 (6.9)	29 (11.7)	-0.17	7.0%	11.2%	-0.15
Carvedilol	725	29 (6.1)	21 (8.5)	-0.09	6.2%	6.6%	-0.02
Other beta-blockers	725	191 (40.0)	50 (20.2)	0.44	38.2%	23.5%	0.32
Calcium channel blockers	725	175 (36.6)	91 (36.8)	<0.01	36.0%	35.3%	0.01
MRAs	725	126 (26.4)	88 (35.6)	-0.20	27.6%	35.1%	-0.16
Loop diuretics	725	235 (49.2)	129 (52.2)	-0.06	49.7%	51.2%	-0.03
Thiazide	725	17 (3.6)	14 (5.7)	-0.10	3.8%	4.4%	-0.03
Antiviral treatment for HBV or HCV	725	91 (19.0)	33 (13.4)	0.15	19.1%	12.7%	0.18
PPIs	725	148 (31.0)	86 (34.8)	-0.08	32.1%	35.2%	-0.07
Ursodeoxycholic acid	725	14 (2.9)	4 (1.6)	0.09	2.7%	1.3%	0.10
NSAIDs	725	129 (27.0)	71 (28.7)	-0.04	27.1%	25.4%	0.04
Hypoglycemic agent							
SGLT2i	725	11 (2.3)	1 (0.4)	0.16	2.1%	0.4%	0.15
GLP1RA	725	3 (0.6)	0 (0.0)	0.11	0.5%	0.0%	0.10
Other oral hypoglycemic agents	725	144 (30.1)	61 (24.7)	0.12	31.0%	26.7%	0.10
Insulin	725	58 (12.1)	35 (14.2)	-0.06	13.1%	14.3%	-0.04
Risk score							
CHA ₂ DS ₂ -VASc	725	3.6 ± 1.7	2.9 ± 1.9	0.39	3.5 ± 1.7	3.1 ± 1.8	0.26
HAS-BLED	725	3.9 ± 1.3	3.6 ± 1.5	0.17	3.9 ± 1.3	3.6 ± 1.4	0.20
Charlson comorbidity index	725	6.0 ± 3.3	5.6 ± 3.2	0.10	5.9 ± 3.3	5.8 ± 3.1	0.01
Child–Pugh score	725						
Class A: 5 or 6		265 (55.4)	94 (38.1)	0.35	53.9%	45.3%	0.17

		Before IPTW an	d imputation#	After IPT	After IPTW and imputation\$		
	Available	DOAC	Warfarin				
Variable	number	(<i>n</i> = 478)	(<i>n</i> = 247)	STD	DOAC	Warfarin	STD
Class B: 7–9		190 (39.7)	135 (54.7)	-0.30	40.5%	47.4%	-0.14
Class C: ≥10		23 (4.8)	18 (7.3)	-0.10	5.6%	7.3%	-0.07
Baseline laboratory data							
eGFR, mL/min/1.73 m ²	709	73.3 ± 33.3	79.4 ± 45.4	-0.15	74.0 ± 33.7	78.9 ± 41.7	-0.13
eGFR status	709						
>60		306 (64.6)	155 (66.0)	-0.03	64.7%	67.6%	-0.06
30–60		139 (29.3)	54 (23.0)	0.14	29.2%	23.7%	0.13
<30		29 (6.1)	26 (11.1)	-0.18	6.1%	8.7%	-0.10
Serum creatinine, µmol/L	709	106.1 ±79.6	132.6 ±150.3	-0.19	106.1 ±79.6	123.8 ±123.8	-0.13
Blood urea nitrogen, mmol/L	610	8.2 ± 5.5	9.2 ± 7.8	-0.15	7.9 ± 5.3	8.7 ± 6.5	-0.13
AST, U/L	668	43.8 ± 36.7	50.5 ± 38.2	-0.18	44.0 ± 37.7	46.4 ± 33.8	-0.07
ALT, U/L	715	31.5 ± 27.5	39.9 ± 46.9	-0.22	32.5 ± 29.0	37.0 ± 38.8	-0.13
ALK-P, U/L	484	104.2 ± 78.6	106.1 ± 58.3	-0.03	99.4 ± 68.1	107.4 ± 58.3	-0.13
Albumin level, g/L	725	35.9 ± 6.6	35.8 ± 6.3	0.02	35.7 ± 6.6	35.5 ± 6.1	0.03
Total bilirubin level, μmol/L	725	20.4 ± 17.8	23.2 ± 36.0	-0.10	21.3 ± 21.3	22.5 ± 30.6	-0.04
Total bilirubin status, μmol/L	725						
<34.2		432 (90.4)	217 (87.9)	0.08	89.5%	87.0%	0.08
≥34.2		46 (9.6)	30 (12.1)	-0.08	10.5%	13.0%	-0.08
International normalized ratio (INR)	725	1.2 ± 0.3	1.5 ± 0.6	-0.63	1.2 ± 0.3	1.4 ± 0.5	-0.35
INR status	725						
<1.7		455 (95.2)	180 (72.9)	0.64	93.6%	80.8%	0.39
1.7–2.3		20 (4.2)	36 (14.6)	-0.36	5.3%	11.6%	-0.23
≥2.3		3 (0.6)	31 (12.6)	-0.50	1.1%	7.6%	-0.33
Hemoglobin, g/L	678	120.0 ± 23.8	117.6 ± 24.1	0.10	120.3 ± 23.6	119.5 ± 23.6	0.03
Platelet, count ×10 ³	669	161.8 ± 79.7	157.0 ± 114.7	0.05	162.6 ± 77.2	161.3 ± 103.0	0.01
Fasting glucose, mmol/L	312	6.6 ± 2.1	6.9 ± 3.1	-0.13	6.6 ± 2.0	6.6 ± 2.9	<0.01
Glycated hemoglobin %	426	6.4 + 1.3	6.7 + 1.4	-0.23	6.2 ± 1.2	6.3 ± 1.3	-0.07

	B	Before IPTW an	d imputation#	After IPT	W and imputation	on\$	
	Available	Available DOAC Warfarin					
Variable	number	(<i>n</i> = 478)	(<i>n</i> = 247)	STD	DOAC	Warfarin	STD
Triglyceride, mmol/L	449	1.1 ± 0.7	1.2 ± 0.8	-0.15	1.1 ± 0.6	1.1 ± 0.6	< 0.01
Total cholesterol, mmol/L	474	3.9 ± 1.0	4.1 ± 1.3	-0.16	3.9 ± 1.0	4.1 ± 1.1	-0.14
High-density lipoprotein, mmol/L	420	1.1 ± 0.4	1.1 ± 0.5	-0.05	1.1 ± 0.4	1.2 ± 0.4	-0.15
Low-density lipoprotein, mmol/L	454	2.3 ± 0.9	2.4 ± 1.1	-0.08	2.3 ± 0.8	2.4 ± 0.9	-0.11
Follow-up years	725	2.4 ± 2.0	3.6 ± 2.9	-0.48	2.6 ± 2.2	3.2 ± 2.6	-0.25

Abbreviation: GBM, generalized boosted model; IPTW, inverse probability of treatment weighting; DOAC, direct oral anticoagulant; STD, standardized difference; EGD, esophagogastroduodenoscopy; EV, esophageal varices; GV, gastric varices; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; MRAs, mineralocorticoid receptor antagonists; PPIs, proton pump inhibitors; NSAIDs, nonsteroidal anti-inflammatory drugs; SGLT2i, sodium–glucose cotransporter 2 inhibitors; GLP1RA, glucagon-like peptide 1 receptor agonists; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALK-P, alkaline phosphatase.

Data are presented as frequencies (percentages) and means ± standard deviations or medians [25th, 75th percentiles].

\$ Data are presented as numbers (percentages) and means ± standard deviations or medians [25th, 75th percentiles].

	DOAC		W	/arfarin		
		Incidence		Incidence	aHR (95% CI)	Р
Outcome	Event rate	(95% CI)*	Event rate	(95% CI)*	for DOAC ⁺	value
Primary efficacy outcome						
Ischemic stroke	4.3%	2.0 (1.2–2.7)	4.7%	2.2 (1.3–3.1)	1.05 (0.42–2.61)	0.921
Transient ischemic attack	0.7%	0.3 (0.0–0.6)	0.4%	0.2 (-0.1–0.4)	1.36 (0.18–10.3)	0.764
Systemic embolism	1.9%	0.8 (0.4–1.3)	3.9%	1.8 (1.0–2.6)	0.49 (0.14–1.70)	0.258
Composite outcome	6.7%	3.1 (2.2–4.1)	8.6%	4.1 (2.9–5.4)	0.76 (0.38–1.53)	0.445
Primary safety outcome						
Intracranial hemorrhage	3.3%	1.5 (0.8–2.1)	4.3%	2.0 (1.1–2.8)	0.65 (0.26–1.59)	0.339
Gastrointestinal bleeding	13.1%	6.4 (5.0–7.8)	21.4%	10.8 (8.8–12.9)	0.64 (0.39–1.03)	0.067
Major bleeding	16.9%	8.4 (6.8–10.0)	25.8%	13.7 (11.3–16.1)	0.64 (0.42–0.99)	0.046
Secondary outcomes						
All-cause mortality	42.9%	19.4 (17.0–21.7)	46.3%	20.8 (18.1–23.5)	0.73 (0.54–0.99)	0.047
Myocardial infarction	1.9%	0.9 (0.4–1.4)	1.5%	0.7 (0.2–1.1)	1.20 (0.26–5.61)	0.815
Liver decompensation						
Hepatic encephalopathy	2.5%	1.2 (0.6–1.8)	4.9%	2.2 (1.3–3.1)	NA	NA
New-onset ascites	8.3%	3.8 (2.8–4.9)	10.9%	5.1 (3.7–6.5)	0.65 (0.34–1.23)	0.183
SBP	2.2%	1.0 (0.5–1.5)	4.0%	1.8 (1.0–2.6)	0.69 (0.28–1.74)	0.437
Hepatorenal syndrome	1.6%	0.7 (0.3–1.2)	4.6%	2.1 (1.2–2.9)	NA	NA
Esophageal variceal bleeding	3.4%	1.6 (0.9–2.3)	7.3%	3.4 (2.3–4.6)	0.65 (0.27–1.57)	0.341
New-onset HCC	8.5%	4.1 (3.0–5.2)	6.2%	3.0 (1.9–4.0)	1.70 (0.77–3.78)	0.192
Liver-related death	15.2%	6.9 (5.5–8.3)	21.3%	9.6 (7.7–11.4)	0.66 (0.38–1.15)	0.143

Table 2. Follow-up outcomes during 5-year follow-up of patients with atrial fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-adjusted cohort.

Abbreviations: IPTW, inverse probability of treatment weighting; DOAC, direct oral anticoagulant; HR, hazard ratio; CI, confidence interval; NA, not acceptable; SBP, spontaneous bacterial infection; HCC, hepatocellular carcinoma.

⁺ Additional adjustments were made for age, age group, esophageal/gastric varices–related complications, portal hypertension, radiofrequency ablation, P2Y12, other beta-blockers, CHA₂DS₂-VASc score, international normalized ratio, and INR status.

* Number of events per 100 person-years.

Figure 1. Flow chart for selecting and excluding patients.

Figure 1



Figure 2. Cumulative event rates for primary efficacy outcome (A), major bleeding (B), and all-cause mortality (C) during 5-year follow-up period for patients with atrial fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-adjusted cohort. Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of treatment weighting.

Figure 2A



Figure 2. Cumulative event rates for primary efficacy outcome (A), major bleeding (B), and all-cause mortality (C) during 5-year follow-up period for patients with atrial fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-adjusted cohort. Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of treatment weighting.

Figure 2B



Figure 2. Cumulative event rates for primary efficacy outcome (A), major bleeding (B), and all-cause mortality (C) during 5-year follow-up period for patients with atrial fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-adjusted cohort. Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of treatment weighting.

Figure 2C



Figure 3. Cumulative event rates for primary safety outcome (major bleeding) during 5-year follow-up period for patients with atrial fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-adjusted cohort; results are classified under Child–Pugh class A (A) and Child–Pugh class B or C (B).

Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of treatment weighting.

Figure 3A



Figure 3. Cumulative event rates for primary safety outcome (major bleeding) during 5-year follow-up period for patients with atrial fibrillation and liver cirrhosis who were administered DOACs or warfarin in IPTW-adjusted cohort; results are classified under Child–Pugh class A (A) and Child–Pugh class B or C (B).

Abbreviations: DOAC, direct oral anticoagulant; IPTW, inverse probability of treatment weighting.

Figure 3B

